Descamps Diane, Delaugerre Constance, Masquelier Bernard, Ruffault Annick, Marcelin Anne-Geneviève, Izopet Jacques, Chaix Marie-Laure, Calvez Vincent, Brun-Vézinet Françoise, Costagliola Dominique
Laboratoire de Virologie, CHU Bichat Claude Bernard, Paris, France.
J Med Virol. 2006 Feb;78(2):153-60. doi: 10.1002/jmv.20522.
The performance of French virology laboratories belonging to the ANRS network has been assessed annually for 3 years. The performance of these laboratories was compared between the years 2002 and 2003. Ten and 7 coded samples were sent to 38 virology laboratories in 2002 and 45 virology laboratories in 2003, respectively. Each panel of coded samples included at least one HIV-negative control, a pair of duplicate specimens, samples with a wide range of viral loads, and samples with a large number of resistance mutations. The laboratories used their standard sequencing procedures and were asked to report the amino acids at codons associated with resistance mutations, based on the IAS-USA expert panel list. The reference amino acid sequences were defined as those most frequently reported by the participants. The specificity of detection of RT mutations was significantly better in 2003 (99.9%) than in 2002 (99.7%) (P = 0.05). There was no difference between 2002 and 2003 in the specificity of detection of protease mutations (99.6% and 99.8%) or the sensitivity of detection of RT mutations (98.8% and 98.2%). The sensitivity of detection of protease mutations improved significantly between 2002 and 2003 (97.6% and 99.0%, respectively; P = 0.037). The proportion of laboratories reporting fully accurate results, in terms of amplification, specificity, sensitivity, and reproducibility, tended to increase between 2002 and 2003 (P = 0.077). No errors were made by 19% of laboratories in 2002, compared to 42% in 2003. These results show the value of repeated external quality assessments.
对法国国家艾滋病研究机构(ANRS)网络下属的病毒学实验室的工作表现进行了为期3年的年度评估。比较了这些实验室在2002年和2003年的工作表现。2002年向38个病毒学实验室分别发送了10份编码样本,2003年向45个病毒学实验室分别发送了7份编码样本。每组编码样本至少包括一个HIV阴性对照、一对重复样本、一系列不同病毒载量的样本以及含有大量耐药突变的样本。实验室采用其标准测序程序,并被要求根据美国国际艾滋病协会(IAS-USA)专家小组列表报告与耐药突变相关密码子处的氨基酸。参考氨基酸序列定义为参与者报告频率最高的序列。2003年逆转录酶(RT)突变检测的特异性(99.9%)显著优于2002年(99.7%)(P = 0.05)。2002年和2003年蛋白酶突变检测的特异性(分别为99.6%和99.8%)或RT突变检测的灵敏度(分别为98.8%和98.2%)没有差异。2002年至2003年蛋白酶突变检测的灵敏度显著提高(分别为97.6%和99.0%;P = 0.037)。在扩增、特异性、灵敏度和可重复性方面报告完全准确结果的实验室比例在2002年至2003年期间呈上升趋势(P = 0.077)。2002年19%的实验室没有出现错误,而2003年这一比例为42%。这些结果显示了重复进行外部质量评估的价值。